1.
Martin LJ, Alibhai SM, Komisarenko M, Timilshina N, Finelli A. Identification of subgroups of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone plus prednisone at low- vs. high-risk of radiographic progression: An analysis of COU-AA-302. CUAJ [Internet]. 2018Nov.5 [cited 2019Sep.17];13(6). Available from: https://cuaj.ca/index.php/journal/article/view/5586